Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Atyr Pharma Inc (LIFE)

Atyr Pharma Inc (LIFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,063
  • Shares Outstanding, K 9,352
  • Annual Sales, $ 420 K
  • Annual Income, $ -23,600 K
  • 60-Month Beta 2.25
  • Price/Sales 60.06
  • Price/Cash Flow N/A
  • Price/Book 0.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.18
  • Number of Estimates 3
  • High Estimate 0.25
  • Low Estimate -0.65
  • Prior Year -2.52
  • Growth Rate Est. (year over year) +92.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.13 +35.68%
on 03/19/20
3.78 -23.54%
on 03/09/20
-0.94 (-24.54%)
since 03/06/20
3-Month
2.13 +35.68%
on 03/19/20
7.13 -59.47%
on 01/16/20
-2.88 (-49.91%)
since 01/08/20
52-Week
2.13 +35.68%
on 03/19/20
10.08 -71.33%
on 04/29/19
-4.67 (-61.77%)
since 04/08/19

Most Recent Stories

More News
Prosthetic Heart Valve Market to Witness a Pronounce Growth during 2020 to 2025

The Global is expected to exceed more than USD$ 4 Billion by 2024; Growing at a CAGR of more than 9% in the given forecast period.

ABT : 84.95 (+3.69%)
BSX : 35.56 (+5.55%)
CRY : 18.64 (+1.36%)
EW : 208.62 (+7.13%)
LIFE : 2.89 (+7.84%)
NVCN.TO : 2.15 (+5.39%)
STJ : 80.82 (+0.16%)
Atyr Pharma (LIFE) Reports Q4 Loss, Beats Revenue Estimates (Revised)

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 3.14% and 69.41%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

LIFE : 2.89 (+7.84%)
Atyr Pharma (LIFE) Reports Q4 Loss, Lags Revenue Estimates

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 3.14% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

LIFE : 2.89 (+7.84%)
Atyr Pharma: 4Q Earnings Snapshot

SAN DIEGO (AP) _ Atyr Pharma Inc. (LIFE) on Thursday reported a loss of $6 million in its fourth quarter.

LIFE : 2.89 (+7.84%)
aTyr Pharma Announces Fourth Quarter and Full Year 2019 Results and Provides Corporate Update

Company to host conference call and webcast today at 5:00 p.m. EDT / 2:00 p.m. PDT

LIFE : 2.89 (+7.84%)
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Government Grant to Fund Bispecific Antibody Development Platform

Grant awarded by the Hong Kong Government's Innovation and Technology Commission under the Partnership Research Program

LIFE : 2.89 (+7.84%)
aTyr Pharma to Announce Fourth Quarter and Full Year End 2019 Financial Results on March 26th

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report fourth...

LIFE : 2.89 (+7.84%)
Leading Cancer Researcher Dr. Arthur M. Mercurio Joins aTyr as Scientific Advisor

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the appointment of Arthur...

LIFE : 2.89 (+7.84%)
aTyr Pharma Announces Exercise and Closing of Over-Allotment Option in Public Offering

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the underwriters of its...

LIFE : 2.89 (+7.84%)
Roche's Esbriet Gets FDA Breakthrough Tag for New Indication

Roche (RHHBY) gets Breakthrough Therapy status from the FDA for Esbriet in adults with unclassifiable interstitial lung disease.

RHHBY : 40.3600 (+0.85%)
PFE : 34.45 (+2.50%)
NVS : 86.08 (+2.49%)
LIFE : 2.89 (+7.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade LIFE with:

Business Summary

aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States.

See More

Key Turning Points

2nd Resistance Point 2.90
1st Resistance Point 2.79
Last Price 2.89
1st Support Level 2.60
2nd Support Level 2.53

See More

52-Week High 10.08
Fibonacci 61.8% 7.04
Fibonacci 50% 6.10
Fibonacci 38.2% 5.17
Last Price 2.89
52-Week Low 2.13

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar